Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium channel subfamily H member 2 (hERG) is a voltage-gated potassium ion channel encoded by the KCNH2 gene in humans. It forms the pore-forming alpha subunit of the rapid component of the delayed rectifier potassium current (I_Kr), which is essential for repolarizing cardiac action potentials and thus for normal heart rhythm. Dysfunction or inhibition leads to prolonged QT interval on ECGs—a risk factor for arrhythmias such as torsade de pointes and sudden cardiac death. Drug-induced hERG inhibition is a major concern in pharmaceutical safety testing.
Inhibition of I_Kr current, leading to QT interval prolongation.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium Channel Subfamily H Member 2 (hERG).